East Hanover, New Jersey 07936

  • Dyspepsia

Purpose:

Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.


Criteria:

Inclusion Criteria: - Female patients 18 years or older. - Self-reported presence of symptoms consistent with dyspepsia (including mid-upper abdominal discomfort characterized by post prandial fullness, early satiety and bloating) - Stable dose PPI therapy of at least 4 weeks Exclusion Criteria: - History of intestinal obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or of abdominal adhesions. - Evidence that the dyspeptic symptoms are relieved by defecation and/or associated with a change in frequency or stool form. - With a current most bothersome symptom of heartburn. Other protocol-defined inclusion/exclusion criteria may apply.


NCT ID:

NCT00171470


Primary Contact:

Study Director
Novartis
Novartis


Backup Contact:

N/A


Location Contact:

East Hanover, New Jersey 07936
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.